Huawei Builds an iSuperSite Showcase in Collaboration with China Mobile Zhejiang and the China Mobile Design Institute

SHENZHEN, China, Nov. 15, 2021 /PRNewswire/ — Huawei’s iSuperSite showcase, a joint venture with China Mobile Zhejiang and the China Mobile Design Institute in Hangzhou, has recently been accepted.

The site has been upgraded with the Huawei iSuperSite solution since August of this year. The original six cabinets were replaced by just one, minimizing grid power consumption. The site was then selected as a green and energy-saving demo site by China Mobile Zhejiang as part of its carbon emission reduction campaign. The upgraded site not only halves electricity fees and cuts O&M costs by 75%, it also reduces carbon emissions by eight tons per year.

50%+ Savings

Before reconstruction, the site had six cabinets and six separate cooling systems with individual installation space and power supply systems. However, this resulted in a large footprint, low power system efficiency, and significant power consumption.

Following implementation of the Huawei iSuperSite solution, the power supplies, devices, and batteries from the existing six cabinets have been integrated into just one. 80% of floor space is reclaimed in this manner, allowing for the installation of a Huawei iPV power generation system to supply solar energy. Compared with traditional PV power generation system, Huawei’s iPV boasts 20% more energy yield and electricity cost savings of US$2,000 per year, equivalent to a carbon emissions reduction of 8 tons. Prior to the upgrade, the site’s annual electricity fee was approximately US$3,500.

Comparison before and after the "1 for 6" reconstruction

The upgraded site echoes the carbon peak and carbon neutrality campaign launched by China Mobile on July 15 of this year in terms of energy saving, consumption reduction, and carbon emissions reduction. Regarding the campaign, China Mobile summed up its future development goals as energy saving, clean energy, and enablement, and determined the following six paths: build a green network, promote green energy, build a green supply chain, advocate green offices, enhance green enablement, and create a green culture.

One Lithium Battery, Two Roles

To ensure that network transmission is not interrupted in the case of incidents such as lightning strikes and power outages, a communication base station requires backup battery strings of different sizes.

Huawei iSuperSite replaces lead-acid batteries with CloudLi smart lithium batteries, doubling the power density and upgrading the traditional backup power unit to an intelligent energy storage system. More importantly, the AI intelligent self-staggering feature can store power during off-peak periods and discharge power during peak hours. The electricity cost savings over the course of one year may exceed US$1.5 billion if all communication sites in Hangzhou use this feature (calculated based on the residential electricity price with the smallest difference between peak and off-peak periods).

In addition, Huawei innovatively achieves intelligent power management through four functions: intelligent metering, backup power slicing, software-defined, and power audit to improve management efficiency, accelerate the realization of carbon emission reduction goals, and reduce maintenance costs.

The intelligent power system also supports remote and intelligent O&M, reducing O&M costs by 75%, deploying 5G without increasing OPEX, and helping carriers embark on a sustainable development path involving energy saving, consumption reduction, and carbon reduction.

The convergence of 5G, cloud computing, edge computing, and AI technologies in the context of “new infrastructure” has presented a diverse range of possibilities for digital transformation. Energy, as the cornerstone of a digital society, will inject momentum into the development of the digital economy. In the context of China’s national goals, which involve reaching a carbon peak by 2030 and achieving carbon neutrality by 2060, various industries are about to undergo a broad and profound systematic transformation. Energy conservation, consumption reduction, and carbon emission reduction are essential to ensuring sustainable development of the communications industry.

The Huawei iSuperSite solution integrates digital, power electronics, and ICT technologies, helping carriers to upgrade and reconstruct existing sites while saving power and space. This solution not only meets the requirements for the rapid coverage of communications networks in the 5G era, but also minimizes energy consumption, enabling carriers to achieve their carbon emission goals and build a green future together.

Photo – https://mma.prnewswire.com/media/1688140/image.jpg

An Outstanding Enterprise Case for Digital Transformation 2020–2021: China Mobile’s FusionDC Data Center

SHENZHEN, China, Nov. 15, 2021 /PRNewswire/ — At the 2021 Information Technology (IT) Market Annual Conference, hosted by CCID Consulting, the China Mobile (Shaanxi) FusionDC Data Center — constructed using Huawei’s next generation prefabricated modular data center solution — has been named an Outstanding Enterprise Case for Digital Transformation 2020–2021. Included on the 2020–2021 Next Generation Information Technology List released by CCID Consulting, this award was one of the four that Huawei data center facility products, solutions, and deployments received, given the company’s advantages in technical architecture and business models.

As an intelligent foundation for digital transformation, the new China Mobile (Shaanxi) FusionDC Data Center promotes the development of Information and Communications Technology (ICT) in Shaanxi Province and the wider Northwest China region, supporting further advancements in science and technology as well as the development of the wider economy and culture.

China Mobile (Shaanxi) FusionDC Data Center

Huawei’s next generation prefabricated modular data center solution integrates a full range of innovative technologies, including the wide use of Artificial Intelligence (AI), a prefabricated modular design, and fully digital lifecycle management. All core subsystems, from IT and power modules to temperature control and smart management platforms, are pre-integrated and tested in the factory, achieving full-stack convergence. This style of construction significantly shortens construction times, reducing the full process from kickoff to go-live delivery, to just six months. Benefiting from Huawei’s unique approach to data center construction, combining intelligence and prefabrication — often coined as intelligent + prefabricated — the China Mobile (Shaanxi) FusionDC Data Center is not only a smart but also green: power consumption is kept to a minimum and Power Usage Effectiveness (PUE) is improved by 8%. This translates into significant energy savings — 57.6 million kWh of electricity — over the data center’s full lifecycle, reducing carbon emissions by 27,000 tones, equivalent to planting 37,000 trees.

In addition, an indirect evaporative cooling solution maximizes the use of natural, free cooling sources, bringing down annual PUE to under 1.25, saving energy compared to a traditional chilled water solution. Elsewhere, an integrated power module solution improves power supply and distribution efficiency by over 3%, reducing costs, improving efficiency, and optimizing processes.

The China Mobile (Shaanxi) FusionDC Data Center also integrates multiple AI features, including predictive maintenance, real-time energy efficiency optimization, and improved Operations and Maintenance (O&M) efficiency and resource utilization.

Together with partners, Huawei is committed to innovating and constructing data centers that are simple, green, smart, and reliable.

About Huawei

Founded in 1987, Huawei is a leading global provider of Information and Communications Technology (ICT) infrastructure and smart devices. We have more than 197,000 employees, and we operate in more than 170 countries and regions, serving more than three billion people around the world.

Our vision and mission is to bring digital to every person, home and organization for a fully connected, intelligent world. To this end, we will drive ubiquitous connectivity and promote equal access to networks; bring cloud and artificial intelligence to all four corners of the earth to provide superior computing power where you need it, when you need it; build digital platforms to help all industries and organizations become more agile, efficient, and dynamic; redefine user experience with AI, making it more personalized for people in all aspects of their life, whether they’re at home, in the office, or on the go. For more information, please visit Huawei online at www.huawei.com or follow us on:

http://www.linkedin.com/company/Huawei
http://www.twitter.com/Huawei 
http://www.facebook.com/Huawei
http://www.youtube.com/Huawei

Photo – https://mma.prnewswire.com/media/1688132/image_1.jpg

Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results

FDA Feedback Supports Planned Emergency Use Authorization (EUA) Submission for ADG20 for Prevention of COVID-19; Interim Clinical Data Package from EVADE Prevention Trial to Support EUA Submission Expected in Second Quarter 2022

Enrollment Progressing in ADG20 STAMP Trial for Treatment of COVID-19; Planned Interim Efficacy Analysis Expected in Second Quarter 2022 to Support Potential EUA Submission

WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today provided an update on its lead COVID-19 antibody program, ADG20, and reported third quarter 2021 financial results. ADG20 is an investigational monoclonal antibody product candidate designed to provide broad and potent neutralizing activity against SARS-CoV-2, including variants of concern, for the prevention and treatment of COVID-19.

“ADG20 continues to be the only monoclonal antibody in late-stage development that has the potential to offer a unique combination of potency, breadth of neutralization across known SARS-CoV-2 variants of concern as well as additional SARS-like viruses with pandemic potential, and durable protection against COVID-19 for up to one year. Further, our single injection delivery avoids the inconveniences associated with IV administration or multiple injections,” said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. “The world continues to face a host of challenges in fully addressing the COVID-19 crisis. Alternatives or supplements to vaccines for the prevention of COVID-19 are needed for immunocompromised individuals and those who remain hesitant to receive a vaccine or to vaccinate their children. Certain patient populations may not be ideal candidates for emerging oral treatment options due to adherence concerns, comorbidities or possible drug interactions. Based on its combined attributes, ADG20 has the potential to be a differentiated alternative for the prevention and treatment of COVID-19 that may address the needs of these populations, and our commitment to its advancement is unwavering.”

“We’ve made significant progress over the course of 2021, and 2022 is set to be a landmark year for Adagio as we prepare for potential EUA submissions for ADG20 for the prevention and treatment of COVID-19,” said Tillman Gerngross, Ph.D., co-founder and chief executive officer of Adagio. “We recently received clear feedback from the FDA on a strategy to submit an EUA for ADG20 for the prevention of COVID-19, and have initiated efforts to expand our clinical program to additional patient subsets, including immunocompromised individuals and children. Our commercial-readiness efforts are well underway and with a strong balance sheet, we are ready to move quickly to enable access to individuals in need of COVID-19 prevention and treatment options, if authorization and/or approval is granted.”

ADG20 COVID-19 Program Updates

Prevention
Adagio continues to enroll adult and adolescent participants in its ongoing, global Phase 3 EVADE clinical trial evaluating ADG20 as a prevention for COVID-19 in both the pre-exposure and recent exposure settings.

  • Adagio has received feedback from the U.S. Food and Drug Administration (FDA) on a data package needed and a pathway for an EUA submission for the pre-exposure prevention of COVID-19
  • Adagio anticipates that the data package to support an EUA for ADG20 will be available in the second quarter of 2022 followed by expected submission to the FDA in the third quarter of 2022
  • Adagio plans to add a new cohort in EVADE to evaluate ADG20 as a preventative option in immunocompromised individuals, with enrollment expected to begin in the first quarter of 2022
  • Adagio also plans to initiate a trial evaluating ADG20 as a vaccine supplement
  • Following discussion with the FDA, Adagio has aligned on a plan to evaluate ADG20 as a preventative option in the pediatric population, with a trial in individuals between two and 11 years of age expected to be initiated by mid-year 2022

Treatment
Adagio continues to enroll patients in its ongoing, global Phase 2/3 STAMP clinical trial evaluating ADG20 as a treatment for COVID-19.

  • Adagio is planning to modify the trial design in order to expand the at-risk patient population eligible for enrollment in STAMP
  • Based on current enrollment, Adagio anticipates reaching the Phase 2 independent data monitoring committee evaluation in the first quarter of 2022 and the interim efficacy analysis in the second quarter of 2022 to potentially support a subsequent EUA submission

Recent ADG20 Data Presentations at ISIRV-WHO and IDWeek2021

  • New in vitro data demonstrated retained neutralizing activity of ADG20 against a diverse panel of circulating SARS-CoV-2 variants, including the newly emerged Lambda, Mu and Delta plus variants. Notably, findings showed that ADG20 demonstrated potent neutralizing activity against all SARS-CoV-2 variants of concern tested, including those with reduced susceptibility to mAb products currently available under EUA or in late-stage development.
  • Data from a six-month evaluation in Adagio’s Phase 1 healthy volunteer trial of ADG20 confirmed the extended half-life of ADG20, which approached 100 days based on data from the 300 mg intramuscular dose that was given as a single injection. In addition, an exploratory analysis showed that 50% serum virus neutralization titers at six months after a 300 mg intramuscular dose of ADG20 were similar to observed peak titers with the mRNA-1273 vaccine and exceeded those achieved with the AZD1222 vaccine series. ADG20 was well-tolerated with no study drug-related adverse events (AEs), serious AEs, or injection-site or hypersensitivity reactions reported through a minimum of three months follow-up across all cohorts.
  • To support dose selection for Adagio’s global Phase 2/3 STAMP and EVADE clinical trials, the company modified an existing quantitative systems pharmacology whole-body physiologically-based pharmacokinetic (QSP/PBPK) model to better characterize the PK of extended half-life mAbs in serum and key sites of viral replication in the respiratory tract. Adagio’s model adequately a priori predicted the observed ADG20 serum PK in non-human primates (NHPs) and humans. The model was further optimized based on data from Adagio’s Phase 1 clinical trial and then applied for dose selection for STAMP and EVADE, ultimately informing selection of the 300 mg intramuscular dose for the trials.

Intellectual Property

On October 29, 2021, the United States Patent and Trademark Office mailed a notice of allowance to the company for a patent application that will provide patent protection for ADG20 in the U.S.

Third Quarter 2021 Financial Results

  • As of September 30, 2021, Adagio had cash, cash equivalents and marketable securities of $666.3 million, which are expected to support the company’s current operating plans into 2023.
  • Research & development expenses including in-process research and development for the third quarter of 2021 were $49.4 million.
  • Selling, general & administrative expenses for the third quarter of 2021 were $11.1 million.
  • Net loss for the third quarter was $60.4 million, or $0.98 per share.

About ADG20
ADG20, an investigational monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is advancing through global clinical trials for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization activity against SARS-CoV-2 and additional clade 1 sarbecoviruses by targeting a highly conserved epitope in the receptor binding domain. ADG20 was further engineered to provide an extended half-life for durable protection. ADG20 has demonstrated potent neutralizing activity against the original SARS-CoV-2 virus, all known SARS-CoV-2 variants of concern and additional SARS-like viruses in preclinical studies. ADG20 is administered in clinical trials by a single intramuscular injection. To date, ADG20 has been well-tolerated in a Phase 1 trial with no safety signals identified through a minimum of three months follow-up across all cohorts. ADG20 has not been approved for use in any country, and safety and efficacy have not yet been established.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, including COVID-19 and influenza. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with the potential for a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple non-competing, broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch, ensuring the potential for broad accessibility to people around the world. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned EUA submissions, initiation, modification and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients, including in specific populations, with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our expectations regarding the scope of any approved indication for ADG20; and the benefits of our product candidates to patients; our manufacturing capabilities and strategy; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, the impacts of the COVID-19 pandemic on our business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, and the uncertainties and timing of the regulatory approval process. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in Adagio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 and in Adagio’s future reports to be filed with the SEC, including Adagio’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

ADAGIO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(In thousands, except share and per share amounts)

September 30,
2021
December 31,
2020
Assets
Current assets:
Cash and cash equivalents $ 478,269 $ 114,988
Marketable securities 188,053
Prepaid expenses and other current assets 13,833 2,394
Total current assets 680,155 117,382
Other non-current assets 6,115
Total assets $ 686,270 $ 117,382
Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable $ 17,564 $ 8,153
Accrued expenses 35,485 4,919
Total current liabilities 53,049 13,072
Early-exercise liability 8 11
Total liabilities 53,057 13,083
Commitments and contingencies
Convertible preferred stock (Series A, B and C) $0.0001 par value; no shares authorized, issued and outstanding at September 30, 2021; 12,647,934 shares authorized, issued and outstanding at December 31, 2020; aggregate liquidation preference of $0 and $169,900 at September 30, 2021 and December 31, 2020, respectively 169,548
Stockholders’ equity (deficit):
Preferred stock:
Undesignated preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2021; no shares authorized at December 31, 2020; no shares issued and outstanding at September 30, 2021 and December 31, 2020
Common stock, $0.0001 par value; 1,000,000,000 shares authorized at September 30, 2021; 150,000,000 shares authorized at December 31, 2020; 111,251,660 shares issued and outstanding at September 30, 2021; 28,193,240 shares issued and 5,593,240 shares outstanding at December 31, 2020 5 1
Treasury stock, at cost; no shares and 22,600,000 shares at September 30, 2021 and December 31, 2020, respectively (85 )
Additional paid-in capital 842,272 154
Accumulated other comprehensive income 3
Accumulated deficit (209,067 ) (65,319 )
Total stockholders’ equity (deficit) 633,213 (65,249 )
Total liabilities, convertible preferred stock and stockholders’ equity (deficit) $ 686,270 $ 117,382

ADAGIO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
(In thousands, except share and per share amounts)

Three Months
Ended
September 30,
Three Months
Ended
September 30,
Nine Months
Ended
September 30,
Period from
June 3, 2020
(Inception) to
September 30,
2021 2020 2021 2020
Operating expenses:
Research and development(1) $ 45,366 $ 7,251 $ 114,465 $ 7,299
Acquired in-process research and development(2) 4,000 39,915 7,500 39,915
Selling, general and administrative 11,052 842 21,853 892
Total operating expenses 60,418 48,008 143,818 48,106
Loss from operations (60,418 ) (48,008 ) (143,818 ) (48,106 )
Other income (expense):
Interest income 48 80
Other expense (5 ) (10 )
Total other income (expense), net 43 70
Net loss (60,375 ) (48,008 ) (143,748 ) (48,106 )
Other comprehensive income (loss)
Unrealized gain on available-for-sale securities, net of tax 3 3
Comprehensive loss $ (60,372 ) $ (48,008 ) $ (143,745 ) $ (48,106 )
Net loss per share attributable to common stockholders, basic and diluted $ (0.98 ) $ (25.98 ) $ (7.06 ) $ (7.55 )
Weighted-average common shares outstanding, basic and diluted 61,297,086 1,847,826 20,346,771 6,375,000

(1)   Includes related-party amounts of $1,826 and $2,261 for the three and nine months ended September 30, 2021, respectively, and $291 for both the three months ended September 30, 2020 and for the period from June 3, 2020 (inception) to September 30, 2020.
(2)   Includes related-party amounts of $4,000 and $7,500 for the three and nine months ended September 30, 2021, respectively, and $39,915 for both the three months ended September 30, 2020 and for the period from June 3, 2020 (inception) to September 30, 2020.

Seegene Opens New Subsidiary in Bogotá, Colombia, to Advance Regional COVID-19 Testing

Company’s eighth global subsidiary will also support regional HPV screening

SEOUL, South Korea, Nov. 15, 2021 /PRNewswire/ — Seegene Inc. (KQ 096530), a leading biotechnology firm specializing in molecular diagnostics (MDx), has announced the opening of an eighth global subsidiary, strategically located in Bogotá, Colombia. The new entity, known as ‘Seegene Colombia S.A.S,’ began operations in mid-October. While the immediate need is for more rapid and accessible COVID-19 testing throughout the region, the subsidiary will also support screening for other viruses such as human papillomaviruses (HPVs).

Logo

Seegene has seven other subsidiaries in the U.S.A., Canada, Germany, Italy, Mexico, Brazil, and the Middle East, which work closely with the company’s headquarters in Seoul, South Korea.

“Geographically, Colombia is located in a really pivotal position at the top of South America, which has struggled immensely with both COVID-19 cases and the emergence of novel SARS-CoV-2 variants,” said Dr. Jong-Yoon Chun, Seegene Founder and CEO. “This makes testing and surveillance even more important from a public health perspective. We believe we’re uniquely placed to address this need, delivering more rapid and accurate assays to Colombia and neighboring countries.”

To date, Colombia has reported nearly five million COVID-19 infections and more than 125,000 related deaths. Tests are typically imported, which can cause delays and restricted access when they’re needed most. Seegene’s Colombian subsidiary, located in Bogotá,-to be staffed with local experts––will provide greater flexibility and supply chain security.

As one of the major SARS-CoV-2 assay providers in Colombia, Seegene will continue to strengthen its position as a key MDx solution provider with a broad product portfolio including HPV, STI, TB and GI assays. The assays detect multiple target pathogens in a single reaction, helping to rapidly identify the cause of an infection. This role in screening infectious diseases will continue with more local resources.

Logo – https://mma.prnewswire.com/media/1357790/Seegene_logo_Logo.jpg

Kikitrade annonce une coentreprise avec Oxford Frontier pour lancer une plateforme de trading d’actifs numériques ciblant les marchés du Moyen-Orient

  • Kikitrade, la plateforme d’investissement social en crypto-monnaies, a annoncé la création d’une coentreprise avec Oxford Frontier, spécialiste des marchés émergents basé au Royaume-Uni, pour lancer une plateforme de négociation d’actifs numériques ciblant les marchés du Moyen-Orient.

HONG KONG, 15 novembre 2021 /PRNewswire/ — Kikitrade a levé un total de $12M en 2021 pour accélérer sa croissance sur les marchés APAC, soutenu par des investisseurs comme le milliardaire britannique des fonds spéculatifs Alan Howard, Dragonfly Capital et la licorne de jeux blockchain Animoca Brands. Elle progresse dans le but de populariser l’adoption des actifs numériques parmi les gens ordinaires, en particulier la génération Z, les milléniaux et les non professionnels de la finance.

Sous l’impulsion des Émirats arabes unis et de Bahreïn, la région du Moyen-Orient développe des régimes réglementaires de plus en plus favorables aux actifs numériques afin d’attirer les talents et les entreprises technologiques. Avec le développement rapide du Metaverse et une acceptation plus large, les actifs basés sur la blockchain deviendront un moteur important de la prochaine vague de technologie financière.

Kikitrade vise à fournir une plateforme d’investissement en crypto-monnaies et à créer une communauté dans une application « interactive et éducative » en intégrant des éléments sociaux et de jeu à la plateforme. Tandis que Kikitrade se concentrera sur le produit et le développement technique pour les investisseurs de détail dans les pays, Oxford Frontier obtiendra des licences locales et localisera la plateforme grâce à ses solides connaissances et son réseau au Moyen-Orient, et à son expertise dans les domaines du commerce en ligne, des marchés de capitaux et de la blockchain. Kikitrade et Oxford Frontier vont créer de profondes synergies après la création de la coentreprise.

Muhammad Ali Khwaja, le PDG d’Oxford Frontier, a déclaré : « Nous sommes encouragés par les initiatives réglementaires au Moyen-Orient et nous pensons que Kikitrade serait la plateforme idéale, en particulier pour les investisseurs qui sont nouveaux dans les actifs numériques, notamment la génération Z. Nous sommes ravis de notre partenariat avec Kikitrade. Nous allons chercher à embaucher une équipe technologique et commerciale pour accélérer son expansion sur le marché. »

Allen Ng, cofondateur de Kikitrade, a déclaré : « Le Moyen-Orient est devenu qui fournit une liste exceptionnelle de clients avec un environnement réglementaire amical pour les actifs numériques. Kikitrade va étendre son expertise en matière de développement de produits et de techniques pour prendre pied sur les marchés du Moyen-Orient. Nous sommes ravis de rejoindre dans cette entreprise Oxford Frontier qui a une connaissance approfondie des entreprises fintech et des marchés du Moyen-Orient. »

À propos de Kikitrade

Kikitrade est une plateforme d’investissement social qui permet aux débutants d’acheter et de gérer des actifs numériques en toute simplicité, avec un montant minimum d’investissement de seulement US$1. L’entreprise a été incubée par Everest Ventures Group (EVG) en 2020, un groupe spécialisé dans les actifs numériques qui a participé à de nombreux projets blockchain de renom. Kikitrade s’efforce d’être la passerelle la plus sûre et la plus conviviale pour les milléniaux et les primo-investisseurs pour commencer leurs investissements en crypto.

Logo – https://mma.prnewswire.com/media/1685730/logo_horizontal_01_Logo.jpg

About 2,722 Candidates write BECE in Asante-Akim South

Juaso (Ash),- A total of 2,722 candidates from 78 Junior High Schools are writing this year’s Basic Education Certificate Examination (BECE) in the Asante Akim South Municipality.

They are made up of 1,430 boys and 1,292 girls.

This was made known by officials of the Municipal Education Directorate when the Municipal Chief Executive ((MCE), Mr. Alexander Frimpong visited the Juaso Senior High School centre.

The MCE was at the centre to encourage the children ahead of the Social Studies and French papers, as the political head of the Municipality.

“I am here on behalf of the Assembly and Traditional Authorities to wish you well in your exams and to encourage you to face the task ahead with a clear conscience,” he stated.

He said the BECE was one of the major hurdles they had to overcome in their academic progression and urged them to enter the exam hall with a positive mind-set.

The BECE, he reminded them, was their first step towards their future careers and that most of the professionals they admired in their communities once sat for the BECE.

“The examination hall is the same as your various classrooms that you have been learning over the years so feel free and answer the questions without panic,” he encouraged them.

Mr. Frimpong also counselled the candidates not to feel intimidated by the presence of the invigilators because they were only there to do their jobs, saying that they had also been students before and for that matter familiar with their situation.

“With the introduction of the Free Senior High School Policy by the President, Nana Addo Dankwa Akufo-Addo, all you need to do is to work hard and get good grades because school fees are not hindrance to secondary school anymore,” the MCE assured.

Madam Elizabeth Davies, the Municipal Director of Education entreated the candidates to overcome any fears they might be harbouring before they entered the examination hall.

She said the questions they were about to answer were not different from what they were taught and urged them to approach the questions with open minds.

Source: Ghana News Agency

About 2584 candidates are writing BECE in the Yendi Municipality

Yendi (NR)- About 2,584 candidates from 41 Junior High Schools including; five private Junior High Schools are writing the Basic Education Certificate Examination (BECE).

The candidates comprise of 1,342 boys and 1,242 girls.

Some 31 candidates made up of 19 boys and 12 girls were absent, while Alhassan Issifu of SDA JHS allegedly died.

The centres included; Dagbong state SHS Centres ‘A’ and B, Yendi SHS Centre A and B, Yendi SHS Centre A, B C. Yendi primary centre A, Gbungbaliga Centre A and 7As COSTECH centre A.

Alhaji Hammed Abubakar Yussif the Yendi Municipal Chief Executive who addressed the candidates before the examination said the final examination of the candidates was the beginning of their lives adding that their parents and teachers had done their part and no teacher would be in the examination hall with them.

He said their past results were not good and called on them to work harder to improve.

Mr. Bright Lawoe the Yendi Municipal Director of Education reminded the candidates that they were at the end of their Junior High School and their performance would determine the schools they would admitted in.

He warned them not to send foreign materials like phones, calculators, wrist watches to examination halls.

Source: Ghana News Agency

Foundation donates bicycles and school bags to children  

Odumase (B/R),- The Fair Gratitude Foundation, a Non-Governmental Organisation (NGO) has presented 25 bicycles, school bags and other items worth GH¢15, 300 to needy, but brilliant school children in the Sunyani West Municipality.

The beneficiary pupils and students, mostly girls according to the NGO, which centred and worked to promote quality education in schools, walked between two and seven kilometres every day to attend classes.

In addition, the organisation presented gas cookers and burners to two deserving teachers in the area, for their selfless services, and to motivate them on their work.

Speaking at at Odumase in the Bono Region, Mr. Williams Ohene-Adjei, the Founder and Executive Director explained the NGO identified the challenges and decided to help alleviate the plight of the school children.

He emphasised education remained the key to success and empowerment, hence the need to support and help sustain the interest of, particularly, girls in schools to enable them to achieve high academic laurels.

Mr. Ohene-Adjei advised parents to spend much of their resources on the education of their children by providing them with basic learning and teaching materials.

Though the government, he added, was doing everything possible to make school environment friendly and conducive for effective teaching and learning, it behooved on stakeholders and wealthy individuals in the area to also support.

Mr. Issah Baffoe, the Sunyani West Municipal Director of Education expressed appreciation to the NGO for the support and asked the students to be motivated by the gesture and concentrate on their studies.

He expressed concern about rising level of drug abuse and alcoholism among Senior High School (SHS) boys in the area, saying the situation worsened in three out of the five SHS in the Municipality.

Mr. Baffoe advised parents to monitor the movements of their children and be interested in the kind of friends they picked to protect them from bad peers whose influence could truncate their education and ruin their future accordingly.

Source: Ghana News Agency